Document is current
Any future updates will be listed below
-
Authors
Spruyt, Laure
Mlinarič, Tjaša
Dusart, Nathalie
Reinartz, Mariska
Van Hulle, Marc M.
Sunaert, Stefan
Van Laere, Koen
Dupont, Patrick
Vandenberghe, Rik
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (G094418N)
KU Leuven Bijzonder Onderzoeksfonds (C14/21/109)
Vlaams Agentschap voor Innovatie en Onderzoek (HBC.2019.2523)
Stichting Alzheimer Onderzoek (2022/0009)
- License Information
-
More Information
Article History
Received: 26 July 2025
Accepted: 26 February 2026
First Online: 6 April 2026
Declarations
:
: The Ethics Committee for Clinical Studies UZ/KU Leuven approved the study (S61444) and all participants provided written informed consent for the use of their clinical data for research purposes, in accordance with the Declaration of Helsinki.
: RV’s institution has clinical trial agreements (RV as PI) with Alector, Biogen, BMS, Denali, Lilly/Prevail, J&J and UCB. RV’s institution has consultancy agreements (RV as DSMB or DMC member) with AC Immune and Novartis. KVL has performed contract research through UZ/KU Leuven as PI for BMS, Celgene, GE Healthcare, J&J, Novartis, Rapport and UCB, and is member of the advisory board for Enigma (USA).
